Showing results (51-60 of 1,629) with videos related to

Sort By:
Pageof 163
Clinical and Translational Medicine|February 26, 2021
FAM83H-AS1 is a noncoding oncogenic driver and therapeutic target of lung adenocarcinomaSiwei Wang, Chencheng Han, Tongyan Liu, et al.
Clinical and Translational Medicine|February 26, 2021
Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trialXiaowei Xu, Wanli Jiang, Lijun Chen, et al.
Clinical and Translational Medicine|February 26, 2021
Membrane engineering of cell membrane biomimetic nanoparticles for nanoscale therapeuticsMinghai Zhang, Shanshan Cheng, Yue Jin, et al.
Clinical and Translational Medicine|February 26, 2021
Hindering triple negative breast cancer progression by targeting endogenous interleukin-30 requires IFNγ signalingCarlo Sorrentino, Stefania Livia Ciummo, Luigi D'Antonio, et al.
Clinical and Translational Medicine|February 22, 2017
Single cell sequencing: a distinct new fieldJian Wang, Yuanlin Song
Clinical and Translational Medicine|October 6, 2019
Debutant iOS app and gene-disease complexities in clinical genomics and precision medicineZeeshan Ahmed, Saman Zeeshan, Ruoyun Xiong, et al.
Clinical and Translational Medicine|April 12, 2025
Transcriptomic miRNA and mRNA signatures in primary prostate cancer that are associated with lymph-node invasionMatias A Bustos, Kelly K Chong, Yoko Koh, et al.
Clinical and Translational Medicine|April 8, 2025
The role of cancer-associated fibroblasts in the tumour microenvironment of urinary systemRi Hong, Puguang Yu, Xiaoli Zhang, et al.
Clinical and Translational Medicine|April 25, 2025
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid LeukemiaManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Clinical and Translational Medicine|April 23, 2025
Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational studyRong Shen, Wei-Guo Cao, Li Wang, et al.
Pageof 163